Benzinga | Jul 30, 2021 07:13AM EDT

SVB Leerink Maintains Underperform on Vertex Pharmaceuticals, Raises Price Target to $175

SVB Leerink analyst Geoffrey Porges maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Underperform and raises the price target from $170 to $175.